As Wall Street awaits key phase III data from Abivax SA with microRNA-124 (miR-124)-targeting obefazimod in ulcerative colitis, due this quarter, the inflammatory bowel disease (IBD) space – which ...

New soliton solutions to the NLSE with parabolic nonlinearity are being explored, featuring conservation laws and pulse ...

A silicon-lithium niobate metasurface controls light through air at gigahertz speeds, advancing compact systems for optical ...

According to a recent exploratory study published in eGastroenterology, the answer is more complex than expected. Researchers from KU Leuven and collaborating institutions conducted a tightly ...

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer ...

Delve into the technical differences between traditional passive charging systems and smart EV chargers that respond to ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Advances in LEDs and LED drivers deliver a range of improvements for automotive and horticultural LED lighting.

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

ACROBiosystems is breaking the chain of chronic suffering and safeguarding intestinal health. Learn how in this article.